Pharma, Pharmaceutics and Biotechnology Conference

This is a vital field because it puts into focus all the effects of drugs on the heart and system of circulation in the treatment of heart disease itself, but also for dealing with complications of infectious diseases. Many pathogens, including viruses, bacteria, and parasites, have strong influences on the state of cardiovascular function, causing myocarditis, endocarditis, or inflammation around the heart, all of which can severely affect the outcome of patient care.

The collision of infectious diseases with cardiovascular health is very relevant, especially as new research reveals how infections-including COVID-19, HIV, and Changes disease-inside the arteries and heart affect and change the heart. For example, viral infections can become myocarditis, inflammation of the heart muscle; bacterial infections, such as streptococcal infections, can cause infective endocarditis, irritating the heart valves and requiring prompt medical attention. Often, cardiovascular pharmacological management of infections involves treatment with other drugs.

Drugs used to manage heart failure, hypertension, and arrhythmias have to be selected cautiously, especially if they are used in combination with antimicrobial therapies. For instance, some antibiotics or antivirals may interfere with cardiovascular drugs either through alterations in drug metabolism or even through undesirable side effects such as the onset of arrhythmias or poor heart function. Apart from managing the existing cardiovascular conditions, pharmacology was also involved in the prevention of cardiovascular complications due to infections.

For instance, anticoagulants are used in patients with COVID-19 avoid developing where intense clotting had been the problem. Antihypertensive drugs were also used for patients with hypertension, which usually worsened due to chronic infections or inflammation.

It will show how infectious diseases inter-relate with cardiovascular pharmacology, embracing the newest treatments and strategies to handle issues in managing cardiovascular health.

The findings will be on drug interaction, complications from cardiovascular infections, and pharmacological relevance to optimizing heart health in the face of infectious disease challenges.